The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Unmet needs in MDS: treating relapse after alloHSCT & TP53-mutated disease
Hege Garelius
• 9 Jun 2022
Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, outlines unmet needs in myelodysplastic syndromes (MDS), which include the treatment of patients who relapse following allogeneic hematopoietic stem cell transplantation (alloHSCT), and the management of patients with TP53 mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
